Clinical Trials Logo

Locally Advanced Disease clinical trials

View clinical trials related to Locally Advanced Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT01664663 Terminated - Clinical trials for Non Small Cell Lung Cancer

Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy

PLANET
Start date: September 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine the valu of individually dose escalated radiotherapy compared with a standard dose of radiotherapy combined with standard concomitant chemotherapy for patients with locally advanced non small cell lung cancer (stage III) with good performance status.

NCT ID: NCT01635270 Completed - Clinical trials for Non-small Cell Lung Cancer

Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma

midP
Start date: September 12, 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to establish on the market and to clinically evaluate a new strategy of treatment for patients with locally advanced non-small cell lung cancer using deformable repositioning of 4D imaging.

NCT ID: NCT01167530 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer

RAD001
Start date: March 2008
Phase: Phase 1
Study type: Interventional

The phase 1 study evaluats RAD001 in combination with radiotherapy in non-small cell lung cancer. First phase of the study:RAD001 (everolimus) will be administered per os every Monday, one week before then during the radiotherapy and will be continued for 3.5 weeks after the end of the radiotherapy. Chemotherapy is given 4.5 weeks after the end of radiotherapy. Three patient cohorts are planned, receiving 10, 20 and 50 mg of RAD001 per week.Second phase of the study:RAD001 (everolimus) will be administered per os every day one week before then during the radiotherapy and will be continued for 3.5 weeks after the end of radiotherapy. Chemotherapy is given 4.5 weeks after the end of radiotherapy. Three patient cohorts are planned, receiving 2.5, 5 and 10 mg of RAD001 per day.The two phases of the study may be conducted independently and in parallel.Radiotherapy: 66 Grays over 6.5 weeks. (5 weekly fractions of 2 Grays)Chemotherapy: 2 cycles: Cisplatin 100 mg/m2 D1, Navelbine 25 mg/m2 D1, D8, every 21 days.